Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib versus placebo for primary warm autoimmune hemolytic anemia (PATHWAY)
MOH_2022-08-16_011986Phase 3Not yet recruiting
- Sponsor
- Incyte
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of parsaclisib in warm autoimmune hemolytic anemia (wAIHA) (3 arms), sponsored by Incyte. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
parsaclisib
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on MOH_2022-08-16_011986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-08-16_011986.